Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy

Area of Science:

• Oncology
• Nanotechnology
• Molecular Biology

Background:

• Lung cancer remains a leading cause of cancer mortality globally, with poor survival rates despite treatment.
• Conventional chemotherapy for lung cancer suffers from severe side effects, poor selectivity, and multidrug resistance.
• Nanoparticle-mediated RNA interference (siRNA) presents a novel therapeutic strategy by targeting oncogenes and resistance genes.

Purpose of the Study:

• To review recent advancements in nanoparticle-mediated siRNA delivery for lung cancer therapy.
• To highlight various nanoparticle systems used for siRNA delivery.
• To discuss the potential of co-delivery strategies and theranostic agents in lung cancer treatment.

Main Methods:

• Review of current literature on nanoparticle-mediated siRNA delivery systems.
• Analysis of lipid, polymeric, and rigid nanoparticle platforms for lung cancer applications.
• Examination of studies involving co-delivery of siRNA with chemotherapy and theranostic agents.

Main Results:

• Nanoparticle systems demonstrate potential for targeted siRNA delivery in lung cancer.
• Lipid, polymeric, and rigid nanoparticles show promise in silencing oncogenes and resistance genes.
• Co-delivery strategies and theranostic agents enhance therapeutic efficacy and monitoring.

Conclusions:

• Nanoparticle-mediated siRNA delivery is a viable and advanced approach for lung cancer treatment.
• Further research into optimized delivery systems and combination therapies is warranted.
• Theranostic applications of these systems offer improved patient management and outcomes.